Observational Study of Secukinumab in Ankylosing Spondylitis Patients in Korea
Studies secukinumab in adults with ankylosing spondylitis who have not used biologic drugs before.
Plain-language title generated from the registry record
Registry title: Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.
Key facts
- Where
- Busan, Gwangju, and Jinju, South KoreaSee the 3 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 40 years old?
Source: NCT06905288, who can take part
Where in South Korea
- BusanBusan, South KoreaTaking people
- GwangjuGwangju, South KoreaTaking people
- JinjuJinju, South KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novartis Pharmaceuticals
- Trial code
- NCT06905288
- Record updated
- 18 August 2026
- Original description
This is an observational study to evaluate the effectiveness and safety of secukinumab in participants with AS who have never used TNFi, JAKi, or IL-17i drugs before.Read full original descriptionShow less
Real-world Observational Study to Evaluate the Effectiveness of Secukinumab in Biologic-naive Ankylosing Spondylitis Patients in Korea
This is an observational study to evaluate the effectiveness and safety of secukinumab in participants with AS who have never used TNFi, JAKi, or IL-17i drugs before.
Inclusion: Subjects diagnosed with ankylosing spondylitis (AS), as defined by the modified 1984 New York criteria; Subjects who have symptoms of active disease at screening and baseline, as evidenced by BASDAI score of ≥ 4; Subjects who have never used TNFi, JAKi, or IL-17i drugs before; Patients suitable for secukinumab treatment within the scope of labeling by the Ministry of Food and Drug Safety; Subjects who have a time of less than 5 years since AS diagnosis; Subjects who are above the age of 18 years and below 40years old; Subjects who give informed consent form to participate in the study.
Exclusion: Subjects who are in a medical or psychological condition which may prevent them from participating in the study for the study period(28±4 weeks); Subjects who have congenital/traumatic spinal deformities; Subjects currently enrolled in other clinical studies; Subjects who have any contraindications to secukinumab treatment.